Himalaya Nutravedics India Ltd. IPO: price band, dates, issue size, business, financials and risks

Himalaya Nutravedics India Ltd. is launching an SME initial public offering (IPO) of ₹26.50 crore with a price band of ₹100 to ₹106 per share and a lot size of 1,200 shares. The issue opens on September 22, 2026 and closes on September 24, 2026. Allotment is scheduled for September 25, 2026 and the shares are slated to list on September 29, 2026. The IPO is entirely a fresh issue (₹26.50 crore) with no offer for sale (OFS), which means the proceeds are intended to go to the company rather than to selling shareholders.

What the company does and how it sells

Himalaya Nutravedics India Limited is a Hyderabad-based manufacturer of Ayurvedic and nutraceutical formulations. Its business model combines (1) selling its own condition-focused products and (2) contract manufacturing for third-party brands. This dual channel matters because it positions the company both as a brand owner in select products and as a manufacturing partner that can use capacity via external orders.

The company operates a single integrated facility described as compliant with WHO-GMP, AYUSH and FSSAI requirements, and capable of producing multiple dosage forms such as softgels, tablets, hard capsules, liquid orals and medicated oils. In go-to-market terms, the company primarily highlights a prescription-adjacent distribution approach. Sales are described as being driven by medical representatives, pharmacies, stockists and super-stockists across multiple Indian states.

In the stated IPO context, the company indicates it is scaling its branded Ayurvedic and nutraceutical portfolio while continuing contract manufacturing to utilise capacity. It also states an intent to strengthen digital outreach and evaluate exports, leveraging its compliant manufacturing setup.

Milestones since incorporation and operating footprint

The company has a relatively short operating history. It commenced business in 2022 as “Himalaya Nutravedics India Private Limited” and began initial sales operations in Andhra Pradesh. In 2022, it also received ISO 22000:2018 certification for food safety management systems, ISO 9001:2015 certification for quality management systems, and WHO-GMP certification.

In 2023, the company expanded sales operations across 12 states, including Telangana, Madhya Pradesh, Assam, Tamil Nadu, Kerala, Punjab, Maharashtra, Karnataka, Rajasthan, West Bengal, Haryana and Gujarat. It also commenced sales operations for Ayurveda products in Andhra Pradesh, Telangana and Madhya Pradesh, and began production of hard-gel capsule formulations.

In 2024, it expanded sales operations to Uttar Pradesh, Jharkhand and Delhi, followed by commencement of sales operations in Uttarakhand in 2025. The company was recognised as a “Startup” by the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, in 2025.

A corporate restructuring milestone came in late 2025: the company converted from a private limited company to a public limited company and was renamed to “Himalaya Nutravedics India Limited” (fresh certificate dated December 12, 2025). For IPO readers, these milestones frame the operating timeline as well as the company’s sales expansion pattern across states.

Issue structure, allocation framework, and proposed use of proceeds

The Himalaya Nutravedics India IPO is a 100% fresh issue with no OFS component. This structure is relevant because fresh issue proceeds, if raised as proposed, can be deployed for the company’s stated objectives.

The company states that it intends to use the proceeds for:

Funding working capital requirements; investment in branding, digital marketing and sales expansion; and general corporate purposes.

Within the disclosed proposed allocation, the company has earmarked ₹13.75 crore for working capital and ₹7.50 crore for branding, digital marketing and sales expansion. General corporate purposes are included as an object, but the amount is not specified in the provided disclosures.

On allocation, the disclosed reservation split provides 50% for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 35% for Retail Individual Investors (RIIs). The disclosures also mention an anchor investor framework within the QIB portion, including that 60% of the QIB allocation is available for anchor investors and that 33.33% of the anchor portion is reserved for domestic mutual funds.

For applicants, the lot size is 1,200 shares, taking the minimum application amount at the upper end of the price band to ₹1,27,200.

Financial trajectory and profitability trend

The company’s reported financials reflect a rising scale over the last three financial years provided (FY2024 to FY2026), with increases in total revenue, profit after tax (PAT), and total assets. Over the same period, the reported PAT margin moves from a low single-digit level in FY2024 to the high teens by FY2026.

Beyond the financial statements, the company discloses operating and return metrics around the IPO period. For FY2026, the reported EBITDA margin is 18.82% and the reported PAT margin is 17.16%. The disclosures also include earnings per share (EPS) of ₹11.72, return on equity (ROE) of 63.87%, return on capital employed (ROCE) of 36.41%, and return on net worth (RoNW) of 45.12%. Leverage, as reflected in the reported debt-to-equity ratio, is 0.31.

Given the company’s stated plan to use a portion of IPO proceeds for working capital and to invest in sales and marketing expansion, post-issue tracking of working capital movement and liquidity indicators becomes an operating monitor alongside revenue growth.

Valuation and market indicators disclosed for the IPO

At the upper end of the price band (₹106), the company discloses a pre-IPO price-to-earnings (P/E) multiple of 9.04 times and a price-to-book multiple of 3.97 times, based on the reported figures provided.

The available grey market premium (GMP) observations in the supplied context show GMP quoted at ₹0 on September 16, 2026 and September 17, 2026 (three timestamped observations are provided, with referenced issue prices shown alongside the GMP). GMP is an unofficial market indicator and can change quickly; these observations are point-in-time snapshots rather than an outcome forecast.

Subscription data in the provided snapshot shows zero bids across categories as of September 17, 2026. Since the IPO is scheduled to open on September 22, 2026, bidding is not yet open at the snapshot time, and category-wise subscription trends will only be meaningful during the subscription window.

Key risks from the disclosures and what to monitor

The risk factors highlighted in the supplied context cluster around brand and regulatory sensitivity, customer concentration, and operational concentration.

One disclosed risk is that the “Himalaya Nutravedics” trademark is opposed. The stated risk implication is that packaging changes could disrupt recognition and add costs during a critical growth phase.

The company’s revenue is described as heavily dependent on Ayurvedic products, which increases sensitivity to demand shifts or regulatory limits affecting Ayurvedic products. The context also flags customer concentration risk: the top 10 customers contribute most revenue, and the loss of a large customer could reduce volumes and affect margins.

Additional threats described include intense competition from established Ayurvedic and nutraceutical brands and regional players; potential regulatory tightening around claims, labelling and evidence that could increase the cost and time to launch products; raw material and supply-chain volatility for botanicals and imported actives; and shifts in prescriber or consumer preferences that could impact demand for certain formulations.

Monitoring points to track, based on the stated business context and disclosed risk factors:

The revenue mix between own-brand products and contract manufacturing, as the company seeks to scale branded products while utilising capacity via third-party manufacturing.

Working capital requirements and funding intensity as distribution expands and as spending on branding, digital marketing and sales expansion is undertaken from the fresh issue proceeds.

Any material development in the opposed trademark and whether the company implements branding or packaging changes.

Progress on digital outreach initiatives and any stated steps on evaluating exports, subject to required approvals.

Complete numeric snapshot

IPO terms and schedule

Key performance indicators and valuation

Category reservations and anchor allocation

Proposed use of fresh issue proceeds

Subscription status (17 Sep 2026)

Grey market premium (GMP) trend

GMP is an unofficial market indicator and can change; these are dated snapshot observations, not a listing forecast.